Related references
Note: Only part of the references are listed.ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease
Philip O. Katz et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)
Convulsive Seizure Due to Hypomagnesemia Caused by Short-term Vonoprazan Intake
Masayuki Aiba et al.
INTERNAL MEDICINE (2022)
Severe Hypomagnesemia Associated with the Long-term Use of the Potassium-competitive Acid Blocker Vonoprazan
Masaru Okamoto et al.
INTERNAL MEDICINE (2022)
A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure
Carmelo Scarpignato et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects
Loren Laine et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2022)
The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan
Darcy J. Mulford et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2022)
Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis
Yuan Cheng et al.
DIGESTIVE DISEASES AND SCIENCES (2021)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2C19and Proton Pump Inhibitor Dosing
John J. Lima et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Marked reduction in the number of white globe appearance lesions in the noncancerous stomach after exchanging vonoprazan for esomeprazole treatment: a follow-up case report
Wataru Miwa et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2021)
The Development of Foveolar-type Gastric Adenocarcinoma during Maintenance Therapy of Vonoprazan for Reflux Esophagitis
Masahiro Saito et al.
INTERNAL MEDICINE (2021)
Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease
Seung Han Kim et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
Chinese expert consensus on gastroesophageal reflux disease in 2020
Ying Lian Xiao et al.
JOURNAL OF DIGESTIVE DISEASES (2021)
Drug-Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients
Yoshiharu Suzuki et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Treatment strategies for reflux esophagitis including a potassium-competitive acid blocker: A cost-effectiveness analysis in japan
Yasuki Habu et al.
JOURNAL OF GENERAL AND FAMILY MEDICINE (2021)
Efficacy of Vonoprazan for 48-Week Maintenance Therapy of Patients with Healed Reflux Esophagitis
Hideki Mizuno et al.
DIGESTION (2020)
Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis
Yinglian Xiao et al.
GUT (2020)
Randomised trial of acid inhibition by vonoprazan 10/20 mg once daily vs rabeprazole 10/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study)
Toshihisa Takeuchi et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Vonoprazan-associated Gastric Mucosal Redness: A Report of Four Cases
Kimitoshi Kubo et al.
INTERNAL MEDICINE (2020)
Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo
Yiran Wang et al.
FRONTIERS IN PHARMACOLOGY (2020)
Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer
Yu Kyung Cho et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Gastroesophageal Reflux Disease: A Review
John Maret-Ouda et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease
Hiroto Miwa et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis
Tomohide Tanabe et al.
ESOPHAGUS (2019)
Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan
Yasuki Habu
INTERNAL MEDICINE (2019)
Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD
Yuta Yokoya et al.
JOURNAL OF GASTROENTEROLOGY (2019)
Esophageal physiologic profiles within erosive esophagitis in China: Predominantly low-grade esophagitis with low reflux burden
Mengyu Zhang et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2019)
Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis
Tadayuki Oshima et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018
Anne F. Peery et al.
GASTROENTEROLOGY (2019)
Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study
Yuji Mizokami et al.
GUT (2018)
Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis
Leonardo H. Eusebi et al.
GUT (2018)
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole
Kiyoshi Ashida et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Influence of potassium-competitive acid blocker on the gut microbiome of Helicobacter pylori-negative healthy individuals
Taketo Otsuka et al.
GUT (2017)
The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors
Hiroshi Yamashita et al.
DIGESTION (2017)
Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1)
Hannah H. Lee et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis
Katsuhiko Iwakiri et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2017)
Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis
Shintaro Hoshino et al.
DIGESTION (2017)
Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
K. Ashida et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study
Yuuichi Sakurai et al.
ADVANCES IN THERAPY (2016)
Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
T. Kagami et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
Kazunari Murakami et al.
GUT (2016)
Asia-Pacific consensus on the management of gastro-oesophageal reflux disease: an update focusing on refractory reflux disease and Barrett's oesophagus
Kwong Ming Fock et al.
GUT (2016)
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
H. Jenkins et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis
K. Ashida et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Acid-inhibitory effects of vonoprazan 20mg compared with esomeprazole 20mg or rabeprazole 10mg in healthy adult male subjects - a randomised open-label cross-over study
Y. Sakurai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
Yuuichi Sakurai et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2015)
Risk Factors in the Development of Esophageal Adenocarcinoma
Heiko Pohl et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease
Philip O. Katz et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Is Proton Pump Inhibitor Therapy for Reflux Esophagitis Sufficient?: A Large Real-world Survey of Japanese Patients
Kazuhide Higuchi et al.
INTERNAL MEDICINE (2013)
Intragastric acidity during the first day following administration of low-dose proton pump inhibitors: A randomized crossover study
Sachio Hata et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2013)
Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing
S. B. Clayton et al.
DISEASES OF THE ESOPHAGUS (2012)
Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes
Seiichi Hayato et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands
Jun Matsukawa et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Systematic review of the epidemiology of gastroesophageal reflux disease in Japan
Yoshikazu Kinoshita et al.
JOURNAL OF GASTROENTEROLOGY (2011)
Characterization of a Novel Potassium-Competitive Acid Blocker of the Gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438)
Jai Moo Shin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Clinical trial: Inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects
Hyung-Keun Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2010)
Long-lasting inhibitors of the gastric H,K-ATPase
Jai Moo Shin et al.
Expert Review of Clinical Pharmacology (2009)
A Randomized, Comparative Trial of a Potassium-Competitive Acid blocker (AZD0865)and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease
John Dent et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis
Peter J. Kahrilas et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people
Xiang-Peng Hu et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2007)
The gastric H,K ATPase as a drug target - Past, present, and future
George Sachs et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2007)
Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase
Karin Gedda et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Persistence and adherence to proton pump inhibitors in daily clinical practice
EM Van Soest et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Acid-suppressive efficacy of a reduced dosage of rabeprazole: Comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry
T Shimatani et al.
DIGESTIVE DISEASES AND SCIENCES (2005)
Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life:: effects on intragastric pH and comparison with esomeprazole in healthy volunteers
JP Galmiche et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression
T Shimatani et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H-2-receptor antagonist
T Shimatani et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Acid suppression in healthy subjects following lansoprazole or pantoprazole
JQ Huang et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors
S Xue et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Share Paper
